OREANDA-NEWS. September 23, 2015. Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has been awarded a Medical Research Scotland Ph.D. studentship in partnership with the University of Strathclyde.

The project titled "Improving control over the mechanical and transport properties of collagen-based scaffolds for tissue engineering and regenerative medicine" will be delivered by the University of Strathclyde and Collagen Solutions plc and is one of only 13 four-year PhD Studentships funded by Medical Research Scotland this year. (http://www.medicalresearchscotland.org.uk)

Collagen, the most widely used matrix for Tissue Engineering and Regenerative Medicine, undergoes a constant process of remodelling in the body, and the balance of its degradation by the cells of the body with new collagen synthesis determines its strength and integrity over time. Thus, there is a clear need for safe and effective methods to control the rate implanted collagen is degraded.

Using a cell culture model researchers at the University of Strathclyde have discovered that, by treating collagen with existing clinically-approved drugs, they are able to slow down the rate at which collagen scaffolds are degraded.  This project will provide further insight into the potential for a wider range of drugs of this class to manipulate collagen degradation profiles. Methods for characterising the mechanical properties of collagen-based scaffolds will also be improved. Working with staff from Collagen Solutions, the data will ultimately be used to design novel collagen-based products for the medical devices market and regenerative medicine markets.                                                                    

Dr Stewart White, Chief Executive Officer of Collagen Solutions plc said: "This studentship is further recognition of the expertise that Collagen Solutions has in the development and manufacture of a wide range of medical grade collagen based products for use in novel regenerative medicine products. The rapid application of new methods for the design and preservation of novel collagen scaffolds will generate   applications for collagen materials where our know-how can be applied to and commercialised with significant benefits for patients."